| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | February 7, 2025 4:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
CARMEL, Ind., May 27, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA) ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today that the Indiana Department of Administration in collaboration with the Family and Social Services Administration/Division of Mental Health and Addiction has recommended Syra Health for contract negotiations to implement Indiana's Child Mental Health Wraparound Access Site. The contract is valued at $5.8 million over three years, with an optional one-year extension. Syra has committed to subcontracting 23.5% of the total contract value to other Indian
CARMEL, Ind., May 20, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA) ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today that its Board of Directors will begin a national search for a new Chief Executive Officer to succeed current CEO Dr. Deepika Vuppalanchi. Dr. Vuppalanchi will serve as interim CEO until a successor is appointed. This leadership transition is part of a strategic succession plan designed to position Syra Health for its next phase of grow
Revenue increase led by Population Health's 261% YoY Expansion Gross Margin Improves Substantially to 31.7%, up 14.6 Percentage Points YoY Continued Efficiency Gains Cut Q1 2025 Net Losses by Over Two Thirds Compared to Q1 2024 A conference call will be held today, Thursday, May 8, at 9:00 am ET CARMEL, Ind., May 8, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA) ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today its financial results for the first quarter ended March 31, 2025.
SC 13G - Syra Health Corp (0001922335) (Subject)
8-K - Syra Health Corp (0001922335) (Filer)
8-K - Syra Health Corp (0001922335) (Filer)
10-Q - Syra Health Corp (0001922335) (Filer)
Revenue increase led by Population Health's 261% YoY Expansion Gross Margin Improves Substantially to 31.7%, up 14.6 Percentage Points YoY Continued Efficiency Gains Cut Q1 2025 Net Losses by Over Two Thirds Compared to Q1 2024 A conference call will be held today, Thursday, May 8, at 9:00 am ET CARMEL, Ind., May 8, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA) ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today its financial results for the first quarter ended March 31, 2025.
Conference call will be held on Thursday, May 8, at 9:00 a.m. ET CARMEL, Ind., May 1, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA), ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today that it will report financial results for the three months ended March 31, 2025, on Thursday, May 8, 2025, before market open. The Company will host a conference call that same day, May 8, 2025, at 9:00 a.m. ET, to discuss the results. Interested parties can access the con
2024 Population Health Revenue Acceleration to 132% YoY Q4 2024 Net Losses Cut Nearly in Half Compared to Q4 2023, Highlighting Major Efficiency Gains Continued Momentum with New Customer Wins and Contract Extensions Driving Sustainable Growth A conference call will be held today, Tuesday, March 11 at 9:00 am ET CARMEL, Ind., March 11, 2025 /PRNewswire/ -- Syra Health Corp. (NASDAQ:SYRA) ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today its financial results for fourth quarter and full year ended December 31, 2024.
CARMEL, Ind., May 20, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA) ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today that its Board of Directors will begin a national search for a new Chief Executive Officer to succeed current CEO Dr. Deepika Vuppalanchi. Dr. Vuppalanchi will serve as interim CEO until a successor is appointed. This leadership transition is part of a strategic succession plan designed to position Syra Health for its next phase of grow
4 - Syra Health Corp (0001922335) (Issuer)
4 - Syra Health Corp (0001922335) (Issuer)
4 - Syra Health Corp (0001922335) (Issuer)
4 - Syra Health Corp (0001922335) (Issuer)